D3 Bio
A Chinese, clinical-stage biotechnology company developing new medicines in oncology and immunology.
The company's lead candidate is D3S-001, a next-generation KRAS G12C inhibitor designed to enhance clinical outcomes by improving KRAS G12C target engagement. As of Q2 2024, D3S-001 is in the global Phase II development stage.
Latest D3 Bio News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze